{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T23:38:37Z","timestamp":1775086717704,"version":"3.50.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-6JY"],"award-info":[{"award-number":["CA209-6JY"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-01164-3","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:34:03Z","timestamp":1763469243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-6704","authenticated-orcid":false,"given":"Mick J. M.","family":"van Eijs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-9059","authenticated-orcid":false,"given":"M. Marlot","family":"van der Wal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3291-5000","authenticated-orcid":false,"given":"Hedi-Britt","family":"Klot\u0161kova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00ebl M. M.","family":"Dautzenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-7271","authenticated-orcid":false,"given":"Mark","family":"Schuiveling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1966-1063","authenticated-orcid":false,"given":"Rik J.","family":"Verheijden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona D. M.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bas","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Nierkens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the UNICIT Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Femke","family":"van Wijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3604-5430","authenticated-orcid":false,"given":"Karijn P. M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8343-1356","authenticated-orcid":false,"given":"Femke","family":"van Wijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"1164_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s43018-024-00730-3","volume":"5","author":"KPM Suijkerbuijk","year":"2024","unstructured":"Suijkerbuijk, K. P. M., van Eijs, M. J. M., van Wijk, F. & Eggermont, A. M. M. Clinical and translational attributes of immune-related adverse events. Nat. Cancer 5, 557\u2013571 (2024).","journal-title":"Nat. Cancer"},{"key":"1164_CR2","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1217\u20131238 (2022).","journal-title":"Ann. Oncol."},{"key":"1164_CR3","doi-asserted-by":"crossref","unstructured":"Brahmer, J. R. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J. Immunother. Cancer 9, e002435 (2021).","DOI":"10.1136\/jitc-2021-002435"},{"key":"1164_CR4","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073\u20134126 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR5","doi-asserted-by":"publisher","first-page":"114172","DOI":"10.1016\/j.ejca.2024.114172","volume":"207","author":"RJ Verheijden","year":"2024","unstructured":"Verheijden, R. J. et al. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma. Eur. J. Cancer 207, 114172 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1164_CR6","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","volume":"26","author":"RJ Verheijden","year":"2020","unstructured":"Verheijden, R. J. et al. Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the dutch melanoma treatment registry. Clin. Cancer Res. 26, 2268\u20132274 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1164_CR7","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","volume":"8","author":"OJ van Not","year":"2022","unstructured":"van Not, O. J. et al. Association of immune-related adverse event management with survival in patients with advanced melanoma. JAMA Oncol 8, 1794\u20131801 (2022).","journal-title":"JAMA Oncol"},{"key":"1164_CR8","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1200\/JCO.24.00191","volume":"42","author":"RJ Verheijden","year":"2024","unstructured":"Verheijden, R. J. et al. Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials. J. Clin. Oncol. 42, 3713\u20133724 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1164_CR9","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1007\/s00262-023-03541-0","volume":"72","author":"MJM van Eijs","year":"2023","unstructured":"van Eijs, M. J. M. et al. Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition. Cancer Immunol. Immunother. 72, 4049\u20134064 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"1164_CR10","doi-asserted-by":"publisher","first-page":"768113","DOI":"10.3389\/fimmu.2021.768113","volume":"12","author":"H den Braanker","year":"2021","unstructured":"den Braanker, H., Bongenaar, M. & Lubberts, E. How to prepare spectral flow cytometry datasets for high dimensional data analysis: a practical workflow. Front. Immunol. 12, 768113 (2021).","journal-title":"Front. Immunol."},{"key":"1164_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cyto.a.24501","volume":"101","author":"A Emmaneel","year":"2022","unstructured":"Emmaneel, A. et al. PeacoQC: peak-based selection of high quality cytometry data. Cytometry A 101, 325\u2013338 (2022).","journal-title":"Cytometry A"},{"key":"1164_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cyto.a.20823","volume":"77","author":"F Hahne","year":"2010","unstructured":"Hahne, F. et al. Per-channel basis normalization methods for flow cytometry data. Cytometry A 77, 121\u2013131 (2010).","journal-title":"Cytometry A"},{"key":"1164_CR13","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/cyto.a.22625","volume":"87","author":"S Van Gassen","year":"2015","unstructured":"Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87, 636\u2013645 (2015).","journal-title":"Cytometry A"},{"key":"1164_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1164_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giy083","volume":"7","author":"L Zappia","year":"2018","unstructured":"Zappia, L. & Oshlack, A. Clustering trees: a visualization for evaluating clusterings at multiple resolutions. Gigascience 7, giy083 (2018).","journal-title":"Gigascience"},{"key":"1164_CR16","doi-asserted-by":"crossref","unstructured":"Osa, A. et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3, e59125 (2018).","DOI":"10.1172\/jci.insight.59125"},{"key":"1164_CR17","doi-asserted-by":"publisher","first-page":"e1420","DOI":"10.1002\/cti2.1420","volume":"11","author":"L Lutter","year":"2022","unstructured":"Lutter, L. et al. Human regulatory T cells locally differentiate and are functionally heterogeneous within the inflamed arthritic joint. Clin. Transl. Immunol. 11, e1420 (2022).","journal-title":"Clin. Transl. Immunol."},{"key":"1164_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jim.2005.03.009","volume":"300","author":"W de Jager","year":"2005","unstructured":"de Jager, W., Prakken, B. J., Bijlsma, J. W. J., Kuis, W. & Rijkers, G. T. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J. Immunol. Methods 300, 124\u2013135 (2005).","journal-title":"J. Immunol. Methods"},{"key":"1164_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"1164_CR20","doi-asserted-by":"publisher","first-page":"e1284723","DOI":"10.1080\/2162402X.2017.1284723","volume":"6","author":"M Tosolini","year":"2017","unstructured":"Tosolini, M. et al. Assessment of tumor-infiltrating TCRV\u03b39V\u03b42 \u03b3\u03b4 lymphocyte abundance by deconvolution of human cancers microarrays. Oncoimmunology 6, e1284723 (2017).","journal-title":"Oncoimmunology"},{"key":"1164_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).","journal-title":"BMC Bioinform."},{"key":"1164_CR22","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/gutjnl-2021-326451","volume":"72","author":"C Argmann","year":"2023","unstructured":"Argmann, C. et al. Biopsy and blood-based molecular biomarker of inflammation in IBD. Gut 72, 1271\u20131287 (2023).","journal-title":"Gut"},{"key":"1164_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1084\/jem.20130301","volume":"211","author":"R Ramesh","year":"2014","unstructured":"Ramesh, R. et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J. Exp. Med. 211, 89\u2013104 (2014).","journal-title":"J. Exp. Med."},{"key":"1164_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.it.2022.01.003","volume":"43","author":"D Morgan","year":"2022","unstructured":"Morgan, D. & Tergaonkar, V. Unraveling B cell trajectories at single cell resolution. Trends Immunol. 43, 210\u2013229 (2022).","journal-title":"Trends Immunol."},{"key":"1164_CR25","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41591-024-02895-x","volume":"30","author":"MF Thomas","year":"2024","unstructured":"Thomas, M. F. et al. Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis. Nat. Med. 30, 1349\u20131362 (2024).","journal-title":"Nat. Med."},{"key":"1164_CR26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","volume":"182","author":"AM Luoma","year":"2020","unstructured":"Luoma, A. M. et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 182, 655\u2013671.e22 (2020).","journal-title":"Cell"},{"key":"1164_CR27","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ccell.2024.04.010","volume":"42","author":"T Gupta","year":"2024","unstructured":"Gupta, T. et al. Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis. Cancer Cell 42, 797\u2013814.e15 (2024).","journal-title":"Cancer Cell"},{"key":"1164_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bfgp\/elac044","volume":"22","author":"T Sundell","year":"2022","unstructured":"Sundell, T. et al. Single-cell RNA sequencing analyses: interference by the genes that encode the B-cell and T-cell receptors. Brief. Funct. Genom. 22, 263\u2013273 (2022).","journal-title":"Brief. Funct. Genom."},{"key":"1164_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014).","journal-title":"Genome Biol"},{"key":"1164_CR30","unstructured":"Baumann, E. et al. HoVer-NeXt: a fast nuclei segmentation and classification pipeline for next generation histopathology. in Proceedings of Machine Learning Research (2024)."},{"key":"1164_CR31","doi-asserted-by":"publisher","unstructured":"Graham, S. et al. Lizard: a large-scale dataset for colonic nuclear instance segmentation and classification. arXiv https:\/\/doi.org\/10.48550\/arxiv.2108.11195 (2021).","DOI":"10.48550\/arxiv.2108.11195"},{"key":"1164_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"1164_CR33","unstructured":"Butler, H. et al. The GeoJSON Format RFC 7946. https:\/\/datatracker.ietf.org\/. https:\/\/datatracker.ietf.org\/doc\/rfc7946\/ (2017)."},{"key":"1164_CR34","doi-asserted-by":"crossref","unstructured":"Naidoo, J. et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J. Immunother. Cancer 11, e006398 (2023).","DOI":"10.1136\/jitc-2022-006398"},{"key":"1164_CR35","doi-asserted-by":"crossref","unstructured":"Daetwyler, E. et al. Corticosteroid-resistant immune-related adverse events: a systematic review. J. Immunother. Cancer 12, e007409 (2024).","DOI":"10.1136\/jitc-2023-007409"},{"key":"1164_CR36","doi-asserted-by":"publisher","first-page":"6686","DOI":"10.1073\/pnas.1913940117","volume":"117","author":"BP Nicolet","year":"2020","unstructured":"Nicolet, B. P. et al. CD29 identifies IFN-\u03b3-producing human CD8\u2009+\u2009T cells with an increased cytotoxic potential. Proc. Natl. Acad. Sci. USA 117, 6686\u20136696 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1164_CR37","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1002\/art.30418","volume":"63","author":"MI Koenders","year":"2011","unstructured":"Koenders, M. I. et al. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1\u03b2, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum 63, 2329\u20132339 (2011).","journal-title":"Arthritis Rheum"},{"key":"1164_CR38","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00535-007-2091-3","volume":"42","author":"Y Yagi","year":"2007","unstructured":"Yagi, Y., Andoh, A., Inatomi, O., Tsujikawa, T. & Fujiyama, Y. Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblasts. J. Gastroenterol. 42, 746\u2013753 (2007).","journal-title":"J. Gastroenterol."},{"key":"1164_CR39","doi-asserted-by":"publisher","first-page":"H3356","DOI":"10.1152\/ajpheart.00928.2007","volume":"293","author":"DM Cortez","year":"2007","unstructured":"Cortez, D. M. et al. IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1\/2-dependent C\/EBP-beta, NF-kappaB, and AP-1 activation. Am. J. Physiol. Heart Circ. Physiol. 293, H3356\u2013H3365 (2007).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1164_CR40","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","volume":"9","author":"NR Sproston","year":"2018","unstructured":"Sproston, N. R. & Ashworth, J. J. Role of C-reactive protein at sites of inflammation and infection. Front. Immunol. 9, 754 (2018).","journal-title":"Front. Immunol."},{"key":"1164_CR41","doi-asserted-by":"crossref","unstructured":"Vuyyuru, S. K., Nardone, O. M. & Jairath, V. Predicting outcome after acute severe ulcerative colitis: a contemporary review and areas for future research. J. Clin. Med. 13, 4509 (2024).","DOI":"10.3390\/jcm13154509"},{"key":"1164_CR42","doi-asserted-by":"crossref","unstructured":"Wang, R. et al. Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis. Sci. Immunol. 8, eadd1591 (2023).","DOI":"10.1136\/annrheumdis-2022-eular.3779"},{"key":"1164_CR43","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s43018-024-00810-4","volume":"5","author":"F Dimitriou","year":"2024","unstructured":"Dimitriou, F. et al. A targetable type III immune response with increase of IL-17A expressing CD4\u2009+\u2009T\u2009cells is associated with immunotherapy-induced toxicity in melanoma. Nat. Cancer 5, 1390\u20131408 (2024).","journal-title":"Nat. Cancer"},{"key":"1164_CR44","doi-asserted-by":"crossref","unstructured":"Franken, A. et al. Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis. J. Immunother. Cancer 10, e005323 (2022).","DOI":"10.1136\/jitc-2022-005323"},{"key":"1164_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29539-3","volume":"13","author":"ST Kim","year":"2022","unstructured":"Kim, S. T. et al. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat. Commun. 13, 1970 (2022).","journal-title":"Nat. Commun."},{"key":"1164_CR46","unstructured":"Thimmapuram, R. et al. Identification of biomarkers predicting steroid resistance in immune checkpoint inhibitor-induced arthritis. Arthritis Rheumatol. 75 (2023)."},{"key":"1164_CR47","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","volume":"40","author":"Y Hailemichael","year":"2022","unstructured":"Hailemichael, Y. et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40, 509\u2013523.e6 (2022).","journal-title":"Cancer Cell"},{"key":"1164_CR48","doi-asserted-by":"crossref","unstructured":"Fa\u2019ak, F. et al. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J. Immunother. Cancer 11, e006814 (2023).","DOI":"10.1136\/jitc-2023-006814corr1"},{"key":"1164_CR49","doi-asserted-by":"publisher","first-page":"e0276294","DOI":"10.1371\/journal.pone.0276294","volume":"17","author":"BP Nicolet","year":"2022","unstructured":"Nicolet, B. P. & Wolkers, M. C. The relationship of mRNA with protein expression in CD8\u2009+\u2009T cells associates with gene class and gene characteristics. PLoS One 17, e0276294 (2022).","journal-title":"PLoS One"},{"key":"1164_CR50","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaci.2021.12.769","volume":"149","author":"Y Xie","year":"2022","unstructured":"Xie, Y., Abel, P. W., Casale, T. B. & Tu, Y. TH17 cells and corticosteroid insensitivity in severe asthma. J. Allergy Clin. Immunol. 149, 467\u2013479 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1164_CR51","doi-asserted-by":"crossref","unstructured":"Koetzier, S. C. et al. Brain-homing CD4\u2009+\u2009T cells display glucocorticoid-resistant features in MS. Neurol. Neuroimmunol. Neuroinflamm. 7, e894 (2020).","DOI":"10.1212\/NXI.0000000000000894"},{"key":"1164_CR52","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/all.13051","volume":"72","author":"J Banuelos","year":"2017","unstructured":"Banuelos, J., Cao, Y., Shin, S. C. & Lu, N. Z. Immunopathology alters Th17 cell glucocorticoid sensitivity. Allergy 72, 331\u2013341 (2017).","journal-title":"Allergy"},{"key":"1164_CR53","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41574-022-00745-9","volume":"19","author":"K Devine","year":"2023","unstructured":"Devine, K. et al. The ATP-binding cassette proteins ABCB1 and ABCC1 as modulators of glucocorticoid action. Nat. Rev. Endocrinol. 19, 112\u2013124 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1164_CR54","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fendo.2017.00016","volume":"8","author":"K Scheschowitsch","year":"2017","unstructured":"Scheschowitsch, K., Leite, J. A. & Assreuy, J. New insights in glucocorticoid receptor signaling-more than just a ligand-binding receptor. Front. Endocrinol. (Lausanne) 8, 16 (2017).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"1164_CR55","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1365-2249.1992.tb03084.x","volume":"88","author":"MA Nieto","year":"1992","unstructured":"Nieto, M. A., Gonz\u00e1lez, A., Gamb\u00f3n, F., D\u00edaz-Espada, F. & L\u00f3pez-Rivas, A. Apoptosis in human thymocytes after treatment with glucocorticoids. Clin. Exp. Immunol. 88, 341\u2013344 (1992).","journal-title":"Clin. Exp. Immunol."},{"key":"1164_CR56","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1365-2249.1996.tb08306.x","volume":"103","author":"L Lanza","year":"1996","unstructured":"Lanza, L. et al. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin. Exp. Immunol. 103, 482\u2013490 (1996).","journal-title":"Clin. Exp. Immunol."},{"key":"1164_CR57","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","volume":"6","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih, H. et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J. Immunother. Cancer 6, 95 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"1164_CR58","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41416-020-0882-y","volume":"123","author":"VTF Cheung","year":"2020","unstructured":"Cheung, V. T. F. et al. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br. J. Cancer 123, 207\u2013215 (2020).","journal-title":"Br. J. Cancer"},{"key":"1164_CR59","doi-asserted-by":"publisher","first-page":"e000278","DOI":"10.1136\/esmoopen-2017-000278","volume":"3","author":"MH Geukes Foppen","year":"2018","unstructured":"Geukes Foppen, M. H. et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 3, e000278 (2018).","journal-title":"ESMO Open"},{"key":"1164_CR60","doi-asserted-by":"crossref","unstructured":"Mooradian, M. J. et al. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J. Immunother. Cancer 8, e000451 (2020).","DOI":"10.1136\/jitc-2019-000451"},{"key":"1164_CR61","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.gie.2024.01.024","volume":"100","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients. Gastrointest. Endosc. 100, 273\u2013282.e4 (2024).","journal-title":"Gastrointest. Endosc."},{"key":"1164_CR62","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/apt.16142","volume":"53","author":"RK Pai","year":"2021","unstructured":"Pai, R. K. et al. The significance of histological activity measurements in immune checkpoint inhibitor colitis. Aliment. Pharmacol. Ther. 53, 150\u2013159 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1164_CR63","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.cgh.2020.09.046","volume":"19","author":"A Gupta","year":"2021","unstructured":"Gupta, A., Yu, A., Peyrin-Biroulet, L. & Ananthakrishnan, A. N. Treat to target: the role of histologic healing in inflammatory bowel diseases: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 19, 1800\u20131813.e4 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1164_CR64","doi-asserted-by":"crossref","unstructured":"Vespa, E. et al. Histological scores in patients with inflammatory bowel diseases: the state of the art. J. Clin. Med. 11, 939 (2022).","DOI":"10.3390\/jcm11040939"},{"key":"1164_CR65","doi-asserted-by":"publisher","first-page":"114028","DOI":"10.1016\/j.ejca.2024.114028","volume":"203","author":"T Ruf","year":"2024","unstructured":"Ruf, T. et al. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors. Eur. J. Cancer 203, 114028 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1164_CR66","doi-asserted-by":"crossref","unstructured":"Ma, C. et al. Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis. J. Immunother. Cancer 10, e004560 (2022).","DOI":"10.1136\/jitc-2022-004560"},{"key":"1164_CR67","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s43018-023-00572-5","volume":"4","author":"C Sung","year":"2023","unstructured":"Sung, C. et al. Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer. Nat. Cancer 4, 844\u2013859 (2023).","journal-title":"Nat. Cancer"},{"key":"1164_CR68","doi-asserted-by":"crossref","unstructured":"Kim, G. D. et al. Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC. J. Immunother. Cancer 13, e011636 (2025).","DOI":"10.1136\/jitc-2025-011636"}],"updated-by":[{"DOI":"10.1038\/s43856-026-01388-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000}}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01164-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01164-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01164-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T08:03:03Z","timestamp":1769241783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01164-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1164"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01164-3","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s43856-026-01388-x","URL":"https:\/\/doi.org\/10.1038\/s43856-026-01388-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.J.M.v.E., M.M.v.d.W., H.B.K., N.M.M.D., M.S., R.J.V., F.D.M.v.S., B.O., S.N.: none. K.P.M.S.: Consulting\/advisory relationship: Abbvi,e, Sairopa. Research funding: TigaTx, Bristol Myers Squibb, Philips, Genmab, Pierre Fabre. Honoraria: Bristol Myers Squibb. All paid to institution. F.W.: has advisory relationships with Janssen and Takeda, and received research funding from Takeda, Galapagos, BMS, Sanofi, and Leo Pharma.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"472"}}